Metabolomics Market Size, Share, and Analysis, By Product and Service (Metabolomics Instruments, Separation Tools, and Detection Tools), By Application (Biomarker discovery, Drug Discovery, Personalized Medicine, Toxicology Testing, Nutrigenomics, Functional Genomics, Other Applications), By Indication (Cancer, Neurological Disorders, Cardiovascular Diseases, Inborn Errors of Metabolism, Other), By End-User (Contract Research Organizations, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Other End-users) and By Region (North America, Europe, Asia-Pacific, And Rest of the World) And Regional Forecast 2024-2034
Metabolomics Market Size, Share, and Analysis, By Product and Service (Metabolomics Instruments, Separation Tools, and Detection Tools), By Application (Biomarker discovery, Drug Discovery, Personalized Medicine, Toxicology Testing, Nutrigenomics, Functional Genomics, Other Applications), By Indication (Cancer, Neurological Disorders, Cardiovascular Diseases, Inborn Errors of Metabolism, Other), By End-User (Contract Research Organizations, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Other End-users) and By Region (North America, Europe, Asia-Pacific, And Rest of the World) And Regional Forecast 2024-2034
PRODUCT OVERVIEW
Metabolomics Market is anticipated to grow at a CAGR of 13.8%% in the forecast period (2024-2034), with the market size valued at USD 3 billion in 2023 and projected to reach USD 12.3 billion by 2034.
Metabolomics is the comprehensive study of metabolites, the small molecules involved in metabolic processes within a biological organism. This field focuses on analyzing and quantifying metabolic profiles to understand both normal and abnormal physiological conditions. By employing advanced techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy, metabolomics provides insights into biomarker identification, pharmaceutical research, and personalized healthcare. It enables the detection of biochemical changes associated with diseases, facilitating early diagnosis and personalized treatment strategies. Additionally, metabolomics contributes to fields such as toxicology testing, nutrigenomics, and functional genomics by elucidating metabolic responses and interactions. Overall, metabolomics bridges the gap between genotype and phenotype, offering a comprehensive understanding of metabolic pathways and their implications for health and disease.
MARKET HIGHLIGHTS
Metabolomics Market is expected to reach $12.3 billion, with a growth rate of 13.8% during the forecast period. This growth is driven by the increasing importance of personalized medicine and precision health. The rising incidence of chronic diseases and the need for early and accurate diagnosis are major factors fueling the demand for comprehensive metabolic analysis. Technological advancements in mass spectrometry and NMR spectroscopy enhance data accuracy and analytical capabilities, further propelling market growth. Moreover, growing research activities and collaborations in the pharmaceutical and biotechnology sectors are boosting the market. The integration of metabolomics with genomics and proteomics is also expanding the applications in holistic health solutions, driving future market expansion.
Metabolomics Market Segments:
Growth Drivers
Rising Incidence of Chronic Diseases Boost Demand for Advanced Diagnostic Tools
Increasing R&D Investments in Drug Discovery to Boost Market Growth
Restraint
High Cost of Metabolomics Technologies to Restrict Growth and Development Opportunities
Key Players
PRODUCT OVERVIEW
Metabolomics Market is anticipated to grow at a CAGR of 13.8%% in the forecast period (2024-2034), with the market size valued at USD 3 billion in 2023 and projected to reach USD 12.3 billion by 2034.
Metabolomics is the comprehensive study of metabolites, the small molecules involved in metabolic processes within a biological organism. This field focuses on analyzing and quantifying metabolic profiles to understand both normal and abnormal physiological conditions. By employing advanced techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy, metabolomics provides insights into biomarker identification, pharmaceutical research, and personalized healthcare. It enables the detection of biochemical changes associated with diseases, facilitating early diagnosis and personalized treatment strategies. Additionally, metabolomics contributes to fields such as toxicology testing, nutrigenomics, and functional genomics by elucidating metabolic responses and interactions. Overall, metabolomics bridges the gap between genotype and phenotype, offering a comprehensive understanding of metabolic pathways and their implications for health and disease.
MARKET HIGHLIGHTS
Metabolomics Market is expected to reach $12.3 billion, with a growth rate of 13.8% during the forecast period. This growth is driven by the increasing importance of personalized medicine and precision health. The rising incidence of chronic diseases and the need for early and accurate diagnosis are major factors fueling the demand for comprehensive metabolic analysis. Technological advancements in mass spectrometry and NMR spectroscopy enhance data accuracy and analytical capabilities, further propelling market growth. Moreover, growing research activities and collaborations in the pharmaceutical and biotechnology sectors are boosting the market. The integration of metabolomics with genomics and proteomics is also expanding the applications in holistic health solutions, driving future market expansion.
Metabolomics Market Segments:
- By Product and Services
- Metabolomics Instruments
- Separation Tools
- Detection Tools
- By Application
- Biomarker discovery
- Drug Discovery
- Personalized Medicine
- Toxicology Testing
- Nutrigenomics
- Functional Genomics
- Other Applications
- By Indication
- Cancer
- Neurological Disorders
- Cardiovascular Diseases
- Inborn Errors of Metabolism
- Other
- By End User
- Contract Research Organizations
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Other End-users
Growth Drivers
Rising Incidence of Chronic Diseases Boost Demand for Advanced Diagnostic Tools
Increasing R&D Investments in Drug Discovery to Boost Market Growth
Restraint
High Cost of Metabolomics Technologies to Restrict Growth and Development Opportunities
Key Players
- Agilent Technologies Inc.
- Thermo Fisher Scientific Inc.
- Waters Corporation
- Bruker Corporation
- Bio-Rad Laboratories, Inc.
- PerkinElmer Inc.
- Metabolon, Inc.
- Human Metabolome Technologies Inc.
- Shimadzu Corporation
- LECO Corporation
- Evotec SE
- Asuragen Inc.
- GeneBio
- Danaher Corporation
- Sciex (a Danaher Company)
- Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)
- North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAG.R – United States and Canada
- Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
- Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
- Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
- Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 3-month post-sales analyst support.
1.EXECUTIVE SUMMARY
1.1. Regional Market Share
1.2.Business Trends
1.3. Metabolomics Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. RESEARCH METHODOLOGY
2.1.Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4.Primary Research
2.5.Secondary Research
2.5.1.Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. MARKET CHARACTERISTICS
3.1.Market Definition
3.2.Metabolomics Market: COVID-19 Impact
3.3. Key Segmentations
3.4.Key Developments
3.5.Allied Industry Data
4.METABOLOMICS MARKET – INDUSTRY INSIGHTS
4.1. Industry Segmentation
4.2.COVID-19 overview on world economy
4.3.Industry ecosystem Channel analysis
4.4.Innovation & Sustainability
5. MACROECONOMIC INDICATORS
6. RECENT DEVELOPMENTS
7. MARKET DYNAMICS
7.1.Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4.Market Restraints
7.5. Market Trends
8.RISK ANALYSIS
9. MARKET ANALYSIS
9.1.Porters Five Forces
9.2. PEST Analysis
9.2.1.Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10.METABOLOMICS MARKET
10.1.Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. METABOLOMICS MARKET SIZE & FORECAST 2024A-2034F
11.1. Overview
11.2.Key Findings
11.3.Market Segmentation
11.3.1.By Product and Services
11.3.1.1. Metabolomics Instruments
11.3.1.1.1.By Value (USD Million) 2024-2034F
11.3.1.1.2. Market Share (%) 2024-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.2.Separation Tools
11.3.1.2.1. By Value (USD Million) 2024-2034F
11.3.1.2.2.Market Share (%) 2024-2034F
11.3.1.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.3.Detection Tools
11.3.1.3.1. By Value (USD Million) 2024-2034F
11.3.1.3.2.Market Share (%) 2024-2034F
11.3.1.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.2. By Application
11.3.2.1.Biomarker Discovery
11.3.2.1.1. By Value (USD Million) 2024-2034F
11.3.2.1.2.Market Share (%) 2024-2034F
11.3.2.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Drug Discovery
11.3.2.2.1.By Value (USD Million) 2024-2034F
11.3.2.2.2. Market Share (%) 2024-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Personalized Medicine
11.3.2.3.1.By Value (USD Million) 2024-2034F
11.3.2.3.2. Market Share (%) 2024-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.4. Toxicology Testing
11.3.2.4.1.By Value (USD Million) 2024-2034F
11.3.2.4.2. Market Share (%) 2024-2034F
11.3.2.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.5. Nutrigenomics
11.3.2.5.1.By Value (USD Million) 2024-2034F
11.3.2.5.2. Market Share (%) 2024-2034F
11.3.2.5.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.6. Functional Genomics
11.3.2.6.1.By Value (USD Million) 2024-2034F
11.3.2.6.2. Market Share (%) 2024-2034F
11.3.2.6.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.7. Other Applications
11.3.2.7.1.By Value (USD Million) 2024-2034F
11.3.2.7.2. Market Share (%) 2024-2034F
11.3.2.7.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.By Indication
11.3.3.1.Cancer
11.3.3.1.1. By Value (USD Million) 2024-2034F
11.3.3.1.2.Market Share (%) 2024-2034F
11.3.3.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Neurological Disorders
11.3.3.2.1.By Value (USD Million) 2024-2034F
11.3.3.2.2. Market Share (%) 2024-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Cardiovascular Diseases
11.3.3.3.1.By Value (USD Million) 2024-2034F
11.3.3.3.2. Market Share (%) 2024-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.4. Inborn Errors of Metabolism
11.3.3.4.1.By Value (USD Million) 2024-2034F
11.3.3.4.2. Market Share (%) 2024-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.5. Other
11.3.3.5.1.By Value (USD Million) 2024-2034F
11.3.3.5.2. Market Share (%) 2024-2034F
11.3.3.5.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.By End User
11.3.4.1.Contract Research Organization
11.3.4.1.1. By Value (USD Million) 2024-2034F
11.3.4.1.2.Market Share (%) 2024-2034F
11.3.4.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.4.2. Academic and Research Institutes
11.3.4.2.1.By Value (USD Million) 2024-2034F
11.3.4.2.2. Market Share (%) 2024-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.3. Pharmaceutical and Biotechnology Companies
11.3.4.3.1.By Value (USD Million) 2024-2034F
11.3.4.3.2. Market Share (%) 2024-2034F
11.3.4.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.4.Other End-users
11.3.4.4.1.By Value (USD Million) 2024-2034F
11.3.4.4.2. Market Share (%) 2024-2034F
11.3.4.4.3. Y-o-Y Growth (%) 2024-2034F
12.NORTH AMERICA METABOLOMICS MARKET SIZE & FORECAST 2024A-2034F
12.1.Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1.By Product & Services
12.3.2. By Application
12.3.3. By Indication
12.3.4. By End User
12.4. Country
12.4.1.United States
12.4.2. Canada
13.EUROPE METABOLOMICS MARKET SIZE & FORECAST 2024A-2034F
13.1.Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1.By Product & Services
13.3.2. By Application
13.3.3. By Indication
13.3.4. By End User
13.4.Country
13.4.1.Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14.ASIA-PACIFIC METABOLOMICS MARKET SIZE & FORECAST 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3.Market Segmentation
14.3.1.By Product & Services
14.3.2. By Application
14.3.3. By Indication
14.3.4. By End User
14.4. Country
14.4.1.India
14.4.2. China
14.4.3. South Korea
14.4.4.Japan
14.4.5.Rest of APAC
15.MIDDLE EAST AND AFRICA METABOLOMICS MARKET SIZE & FORECAST 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1.By Product & Services
15.3.2. By Application
15.3.3. By Indication
15.3.4. By End User
15.4.Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4.South Africa
15.4.5. Rest of Middle East and Africa
16. LATIN AMERICA METABOLOMICS MARKET SIZE & FORECAST 2024A-2034F
16.1.Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1.By Product & Services
16.3.2. By Application
16.3.3. By Indication
16.3.4. By End User
16.4.Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. COMPETITIVE LANDSCAPE
17.1.Company market share, 2023
17.2. Key player overview
17.3. Key stakeholders
18. COMPANY PROFILES
18.1.Agilent Technologies Inc.
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1.Product Portfolio
18.1.4.2.Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5.Executive Team
18.2. Thermo Fisher Scientific Inc.
18.3. Waters Corporation
18.4. Bruker Corporation
18.5. Bio-Rad Laboratories, Inc.
18.6. PerkinElmer Inc.
18.7. Metabolon, Inc.
18.8. Human Metabolome Technologies Inc.
18.9. Shimadzu Corporation
18.10. LECO Corporation
18.11.Evotec SE
18.12. Asuragen Inc.
18.13. GeneBio
18.14. Danaher Corporation
18.15. Sciex (a Danaher Company)
18.16. Other Prominent Players
19. APPENDIX
20.CONSULTANT RECOMMENDATION
1.1. Regional Market Share
1.2.Business Trends
1.3. Metabolomics Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. RESEARCH METHODOLOGY
2.1.Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4.Primary Research
2.5.Secondary Research
2.5.1.Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. MARKET CHARACTERISTICS
3.1.Market Definition
3.2.Metabolomics Market: COVID-19 Impact
3.3. Key Segmentations
3.4.Key Developments
3.5.Allied Industry Data
4.METABOLOMICS MARKET – INDUSTRY INSIGHTS
4.1. Industry Segmentation
4.2.COVID-19 overview on world economy
4.3.Industry ecosystem Channel analysis
4.4.Innovation & Sustainability
5. MACROECONOMIC INDICATORS
6. RECENT DEVELOPMENTS
7. MARKET DYNAMICS
7.1.Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4.Market Restraints
7.5. Market Trends
8.RISK ANALYSIS
9. MARKET ANALYSIS
9.1.Porters Five Forces
9.2. PEST Analysis
9.2.1.Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10.METABOLOMICS MARKET
10.1.Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. METABOLOMICS MARKET SIZE & FORECAST 2024A-2034F
11.1. Overview
11.2.Key Findings
11.3.Market Segmentation
11.3.1.By Product and Services
11.3.1.1. Metabolomics Instruments
11.3.1.1.1.By Value (USD Million) 2024-2034F
11.3.1.1.2. Market Share (%) 2024-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.2.Separation Tools
11.3.1.2.1. By Value (USD Million) 2024-2034F
11.3.1.2.2.Market Share (%) 2024-2034F
11.3.1.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.3.Detection Tools
11.3.1.3.1. By Value (USD Million) 2024-2034F
11.3.1.3.2.Market Share (%) 2024-2034F
11.3.1.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.2. By Application
11.3.2.1.Biomarker Discovery
11.3.2.1.1. By Value (USD Million) 2024-2034F
11.3.2.1.2.Market Share (%) 2024-2034F
11.3.2.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Drug Discovery
11.3.2.2.1.By Value (USD Million) 2024-2034F
11.3.2.2.2. Market Share (%) 2024-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Personalized Medicine
11.3.2.3.1.By Value (USD Million) 2024-2034F
11.3.2.3.2. Market Share (%) 2024-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.4. Toxicology Testing
11.3.2.4.1.By Value (USD Million) 2024-2034F
11.3.2.4.2. Market Share (%) 2024-2034F
11.3.2.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.5. Nutrigenomics
11.3.2.5.1.By Value (USD Million) 2024-2034F
11.3.2.5.2. Market Share (%) 2024-2034F
11.3.2.5.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.6. Functional Genomics
11.3.2.6.1.By Value (USD Million) 2024-2034F
11.3.2.6.2. Market Share (%) 2024-2034F
11.3.2.6.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.7. Other Applications
11.3.2.7.1.By Value (USD Million) 2024-2034F
11.3.2.7.2. Market Share (%) 2024-2034F
11.3.2.7.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.By Indication
11.3.3.1.Cancer
11.3.3.1.1. By Value (USD Million) 2024-2034F
11.3.3.1.2.Market Share (%) 2024-2034F
11.3.3.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Neurological Disorders
11.3.3.2.1.By Value (USD Million) 2024-2034F
11.3.3.2.2. Market Share (%) 2024-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Cardiovascular Diseases
11.3.3.3.1.By Value (USD Million) 2024-2034F
11.3.3.3.2. Market Share (%) 2024-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.4. Inborn Errors of Metabolism
11.3.3.4.1.By Value (USD Million) 2024-2034F
11.3.3.4.2. Market Share (%) 2024-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.5. Other
11.3.3.5.1.By Value (USD Million) 2024-2034F
11.3.3.5.2. Market Share (%) 2024-2034F
11.3.3.5.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.By End User
11.3.4.1.Contract Research Organization
11.3.4.1.1. By Value (USD Million) 2024-2034F
11.3.4.1.2.Market Share (%) 2024-2034F
11.3.4.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.4.2. Academic and Research Institutes
11.3.4.2.1.By Value (USD Million) 2024-2034F
11.3.4.2.2. Market Share (%) 2024-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.3. Pharmaceutical and Biotechnology Companies
11.3.4.3.1.By Value (USD Million) 2024-2034F
11.3.4.3.2. Market Share (%) 2024-2034F
11.3.4.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.4.Other End-users
11.3.4.4.1.By Value (USD Million) 2024-2034F
11.3.4.4.2. Market Share (%) 2024-2034F
11.3.4.4.3. Y-o-Y Growth (%) 2024-2034F
12.NORTH AMERICA METABOLOMICS MARKET SIZE & FORECAST 2024A-2034F
12.1.Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1.By Product & Services
12.3.2. By Application
12.3.3. By Indication
12.3.4. By End User
12.4. Country
12.4.1.United States
12.4.2. Canada
13.EUROPE METABOLOMICS MARKET SIZE & FORECAST 2024A-2034F
13.1.Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1.By Product & Services
13.3.2. By Application
13.3.3. By Indication
13.3.4. By End User
13.4.Country
13.4.1.Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14.ASIA-PACIFIC METABOLOMICS MARKET SIZE & FORECAST 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3.Market Segmentation
14.3.1.By Product & Services
14.3.2. By Application
14.3.3. By Indication
14.3.4. By End User
14.4. Country
14.4.1.India
14.4.2. China
14.4.3. South Korea
14.4.4.Japan
14.4.5.Rest of APAC
15.MIDDLE EAST AND AFRICA METABOLOMICS MARKET SIZE & FORECAST 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1.By Product & Services
15.3.2. By Application
15.3.3. By Indication
15.3.4. By End User
15.4.Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4.South Africa
15.4.5. Rest of Middle East and Africa
16. LATIN AMERICA METABOLOMICS MARKET SIZE & FORECAST 2024A-2034F
16.1.Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1.By Product & Services
16.3.2. By Application
16.3.3. By Indication
16.3.4. By End User
16.4.Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. COMPETITIVE LANDSCAPE
17.1.Company market share, 2023
17.2. Key player overview
17.3. Key stakeholders
18. COMPANY PROFILES
18.1.Agilent Technologies Inc.
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1.Product Portfolio
18.1.4.2.Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5.Executive Team
18.2. Thermo Fisher Scientific Inc.
18.3. Waters Corporation
18.4. Bruker Corporation
18.5. Bio-Rad Laboratories, Inc.
18.6. PerkinElmer Inc.
18.7. Metabolon, Inc.
18.8. Human Metabolome Technologies Inc.
18.9. Shimadzu Corporation
18.10. LECO Corporation
18.11.Evotec SE
18.12. Asuragen Inc.
18.13. GeneBio
18.14. Danaher Corporation
18.15. Sciex (a Danaher Company)
18.16. Other Prominent Players
19. APPENDIX
20.CONSULTANT RECOMMENDATION
